Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jared Marshall

Physician Assistant, Medical Enfield, CT Physician Assistant

NPI 1265880918 CMS profile 10784700

160 Hazard Ave, Enfield, CT 06082

Open in the dashboard

General payments

$8,044

312 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jared Marshall of Enfield, CT is reported in the CMS Open Payments database as having received $8,044 across 312 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,901 98
2024 General $2,750 125
2023 General $2,059 69
2022 General $1,104 17
2021 General $230 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jared Marshall
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jared Marshall were reported at $1,901. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jared Marshall Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $230 $156 $41–$563 $132
2022 $1,104 $185 $55–$649 $149
2023 $2,059 $199 $58–$717 $160
2024 $2,750 $206 $62–$740 $164
2025 $1,901 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $910 66 payments
  2. Amgen Inc. $808 22 payments
  3. Intuitive Surgical, Inc. $714 3 payments
  4. Janssen Pharmaceuticals, Inc $630 22 payments
  5. Novartis Pharmaceuticals Corporation $530 21 payments
  6. Pfizer Inc. $481 32 payments
  7. E.R. Squibb & Sons, L.L.C. $472 23 payments
  8. Merck Sharp & Dohme Corporation $373 17 payments
  9. Alnylam Pharmaceuticals Inc. $334 10 payments
  10. Abbott Laboratories $310 5 payments
  11. Other $2,483 91 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,224 306 payments
  2. Travel and Lodging $714 3 payments
  3. Education $106 3 payments
Products named General payments · program years 2021–2025
  1. Da Vinci Surgical System $714 3 payments
  2. XARELTO $630 22 payments
  3. Repatha $626 15 payments
  4. VERQUVO $537 25 payments
  5. JARDIANCE Diabetes $515 46 payments
  6. LEQVIO $456 18 payments
  7. CAMZYOS $365 17 payments
  8. JARDIANCE Diabetes $333 19 payments
  9. ENTRESTO $329 13 payments
  10. OPSUMIT $287 11 payments
  11. Other $3,843 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

2,486

Median for Physician Assistant: 241

Drug cost

$631,339

Median for Physician Assistant: $4,110

Branded share of claims

27.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 164 $219,164
Jardiance Empagliflozin Brand 161 $180,932
Farxiga Dapagliflozin Propanediol Brand 76 $86,823
Xarelto Rivaroxaban Brand 31 $46,735
Entresto Sacubitril/Valsartan Brand 20 $32,313
Ozempic Semaglutide Brand 16 $23,205
Repatha Sureclick Evolocumab Brand 18 $12,242
Corlanor Ivabradine Hcl Brand 13 $7,798
Metoprolol Succinate Generic 230 $3,058
Atorvastatin Calcium Generic 193 $2,150

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$36,994

Medicare's payments for the services billed

Medicare patients

271

Average age 80

Services billed

730

152 women, 119 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 54%
Heart failure 52%
Atrial fibrillation 47%
Chronic kidney disease 44%
Diabetes 38%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $337
$337 161 —
Repatha
  • Amgen Inc. $228
$228 18 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $203
$203 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $188
$188 — —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $168
$168 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

312 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record